全面分析表现出坏死、细胞凋亡和血小板活化特征的促凝血小板
2025年5月23日
本方案提供了一套分析促凝血小板所需的综合程序，这些血小板表现出坏死、细胞凋亡和血小板活化的重叠特征。
我们的研究重点是了解血栓形成前状态（例如抗磷脂综合征和癌症）期间的血小板代谢和信号传导，目的是确定新的生物标志物和治疗靶点。我们小组一直处于最近对血小板代谢如何促进血小板活化和血栓形成的兴趣激增的最前沿。准确表征患者循环中的血小板活化状态以确定血栓形成的风险以及抗血小板药物的治疗效果仍然是一项重大挑战。
有氧糖酵解、磷酸戊糖途径和脂肪酸的 β 氧化已被揭示为血小板中标志性的能量代谢途径，其治疗靶向的潜力已被确立。该方案有助于识别和准确表征促凝血小板，不同于促凝血小板，以及因细胞凋亡或坏死而发生细胞死亡的血小板。首先，通过在 100 微升血小板悬液中加入 0.5 微升 0.5 摩尔原液氯化钙溶液，用 2.5 毫摩尔钙补充洗涤过的人血小板。
保持一部分血小板不刺激，并在室温下用凝血酶和惊厥药的组合刺激剩余的部分 15 分钟。刺激后，向 100 μL 刺激的血小板悬液中加入 1 μL 膜联蛋白 V、包装 1 和抗 CD62P 抗体。将血小板在室温下避光孵育 30 分钟。
30 分钟后，加入等体积的 2% 福尔马林固定血小板，然后通过流式细胞术分析样品以定量促凝血小板。对于血小板的制备，将洗涤过的人血小板稀释至每毫升 100 万血小板的浓度，并补充 2.5 毫摩尔钙。用 5 微摩尔 ROD2 标记血小板以进行线粒体钙检测，并在黑暗中孵育 30 分钟。
对于用于 caspase 活化测定的血小板的制备，在用钙补充血小板并刺激一部分后，将活性 caspase 标记模具添加到刺激的血小板悬液中。将血小板在黑暗中孵育 30 分钟。30 分钟后，加入等体积的 2% 福尔马林固定血小板，然后通过流式细胞术分析血小板。
结果表明，凝血酶诱导表达磷脂酰丝氨酸和 P-选择素的血小板比例呈剂量依赖性增加。凝血酶刺激还导致血小板中线粒体钙水平的时间依赖性增加。然而，凝血酶刺激导致血小板线粒体膜电位降低。
凝血酶刺激激活血小板中的 caspase-8 但不激活 caspase-3 或 7。
查看完整文字稿并访问数千部科学视频
概述
本协议概述了分析促凝血小板的程序，这些血小板具有坏死、凋亡和活化的特征。其目的是增进对血栓形成条件下血小板代谢的理解。
关键研究组成部分
科学领域
- 神经科学
- 血小板生物学
- 血栓形成研究
背景
- 血小板代谢在理解血栓形成中至关重要。
- 促血栓形成状态包括抗磷脂综合征和癌症等疾病。
- 表征血小板活化状态对于评估血栓风险至关重要。
- 关键代谢途径包括有氧糖酵解和β氧化。
研究目的
- 识别血栓形成的新型生物标志物。
- 探索与血小板活化相关的治疗靶点。
- 区分促凝血和促血小板聚集的血小板。
使用的方法
- 用钙补充洗涤过的人类血小板。
- 表征血小板活化状态。
- 分析血小板中的代谢途径。
- 对经历细胞死亡的血小板进行功能表征。
主要结果
- 识别出与其他血小板不同的促凝血小板。
- 对代谢在血小板活化中的作用有新的认识。
- 建立潜在的治疗靶点。
- 改善对促血栓形成状态下血小板行为的理解。
结论
- 准确表征血小板对于血栓风险评估至关重要。
- 代谢途径为治疗干预提供了机会。
- 需要进一步研究以探索这些发现在临床环境中的应用。
常见问题
Executive Industry Relevance
Accurate functional characterization of procoagulant platelets is critical for de-risking thrombosis-related targets and understanding platelet-driven mechanisms in prothrombotic states. This protocol enables precise differentiation of platelet subpopulations, supporting predictive confidence in biomarker discovery and therapeutic target validation. Integration of these analyses informs portfolio decisions at the intersection of discovery biology and translational research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of platelet activation pathways relevant to thrombosis and hemostasis.
- Supports biological de-risking by distinguishing procoagulant from proaggregatory platelets and cell death phenotypes.
- Facilitates identification of novel biomarkers and therapeutic targets in platelet-driven disorders.
- Provides mechanistic clarity for target validation in prothrombotic disease models.
Screening & Assay Development
- Establishes validated flow cytometry-based assays for quantifying platelet activation states.
- Standardizes detection of phosphatidylserine exposure, P-selectin expression, and mitochondrial changes.
- Enables reproducible measurement of caspase activation and mitochondrial calcium as quantitative outputs.
- Prepares robust biological systems for downstream compound screening and functional evaluation.
Translational & Preclinical Research
- Aligns platelet activation phenotyping with disease-relevant models such as antiphospholipid syndrome and cancer.
- Supports translational biomarker development by linking metabolic and activation signatures to clinical risk.
- Provides continuity from discovery-stage mechanistic studies to preclinical validation of antiplatelet strategies.
- Enables risk-adjusted advancement of candidates targeting platelet metabolism or activation.
Pipeline & Workflow Integration
This protocol bridges early discovery, assay development, and translational research by enabling functional and metabolic profiling of platelets in prothrombotic contexts.
- Discovery Biology: Supports hypothesis testing on platelet activation mechanisms and metabolic dependencies.
- Screening: Delivers standardized, quantitative readouts for comparing platelet responses to agonists and inhibitors.
- Analytics: Provides flow cytometry-based measurements of phosphatidylserine, P-selectin, mitochondrial calcium, and caspase activity.
- Translational Research: Connects in vitro platelet phenotyping to disease models and biomarker strategies.
- Enterprise Reuse: Offers a reusable analytical platform for diverse thrombosis and platelet biology programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation and mechanistic de-risking of platelet-driven pathways.
- Operational Value: Enhances standardization, reproducibility, and scalability of platelet activation assays.
- Strategic Value: Informs go/no-go decisions and capital allocation by clarifying biological risk in thrombosis research.
- Portfolio Impact: Enables risk-adjusted prioritization of antiplatelet and antithrombotic candidates.
Implementation Considerations
- Requires expertise in platelet biology, flow cytometry, and metabolic assays.
- Demands access to flow cytometers and validated antibody panels for activation markers.
- Necessitates cross-team standardization of sample preparation and gating strategies.
- Adaptation may be needed for different disease models or patient-derived samples.
- Limitations include potential variability in platelet responsiveness and marker expression.
